SYNCROMUNE
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary... platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.
SYNCROMUNE
Industry:
Biotechnology Life Science Pharmaceutical Therapeutics
Founded:
2020-01-01
Address:
Fort Lauderdale, Florida, United States
Country:
United States
Website Url:
http://www.syncromune.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
10 M USD
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Baudax Bio
Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuCâ„¢ platform.
Current Employees Featured
Founder
More informations about "Syncromune"
Company and Leadership — Syncromune® Inc.
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that …See details»
Syncromune - Crunchbase Company Profile & Funding
Syncromuneâ„¢ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid …See details»
Syncromuneâ„¢ - The Org
Syncromuneâ„¢ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the …See details»
Syncromune Company Profile 2024: Valuation, Funding
Syncromune General Information Description. Developer of intratumoral immunotherapy designed to treat metastatic solid tumor cancers. The company's immunotherapy utilizes intratumoral …See details»
Syncromune® - LinkedIn
Syncromune® | 519 followers on LinkedIn. Synchronizing the Power of Immunotherapy® | Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the …See details»
Syncromune - Contacts, Employees, Board Members, Advisors
Syncromune is a clinical stage biopharmaceutical dedicated to the development of better immunotherapies for metastatic solid tumors.See details»
Syncromune® Overview | SignalHire Company Profile
Syncromuneâ„¢ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. ... Organization …See details»
Syncromune, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Syncromune, Inc. of Fort Lauderdale, FL. Get the latest business insights from Dun & Bradstreet.See details»
Syncromune - Funding, Financials, Valuation & Investors
Syncromune is a clinical stage biopharmaceutical dedicated to the development of better immunotherapies for metastatic solid tumors. Search Crunchbase. ... How much funding has …See details»
Syncromune - Overview, News & Similar companies | ZoomInfo.com
Oct 31, 2023 Syncromune is committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing …See details»
Patients — Syncromune® Inc.
Cancer Therapy Powered By You® Syncromune® is at the forefront of developing personalized immunotherapies with the goal of helping patients with advanced cancer. Our therapy is …See details»
Syncromune - VentureRadar
Similar Companies: Tailored Therapeutics USA Privately Held Tailored Therapeutics is an innovative cell therapy company focused on development of cancer treatments sourced from a …See details»
Syncromune - Updates, News, Events, Signals & Triggers
Syncromune is a clinical stage biopharmaceutical dedicated to the development of better immunotherapies for metastatic solid tumors. Search Crunchbase Start Free TrialSee details»
Syncromune’s Innovative Approach to Solid Tumor Immunotherapy
Sep 27, 2024 Syncromune is developing an innovative in situ personalized therapy platform for solid tumor cancers called SYNC-T. This therapy is a combination multi-target biologic …See details»
Syncromune, Inc. to Present at the 2022 BIO CEO & Investor …
FORT LAUDERDALE, Fla.--( BUSINESS WIRE )--Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of intratumoral immunotherapy …See details»
Syncromune - Company Profile - Tracxn
Oct 14, 2024 Syncromune ranks 1,051st among 2447 active competitors. 873 of its competitors are funded while 560 have exited. Overall, Syncromune and its competitors have raised over …See details»
Syncromune - Business Wire
Jul 12, 2023 Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform drug technology optimized for solid tumor …See details»
News & Events — Syncromune® Inc.
May 30, 2024 The Latest Press Releases | Syncromune in the News | Events Press Releases Syncromune to Present at Piper Sandler 36th Annual Healthcare Conference December 2, …See details»
Eucure Biopharma, Syncromune To Develop Intratumoral …
Oct 20, 2022 Beijing-based Eucure Biopharma, a subsidiary of Biocytogen Pharmaceuticals, and US-based Syncromune Inc. have entered a licensing agreement that will combine Eucure’s …See details»